Sanofi India Limited — Results, 17-12-2024: Reply to Clarification- Financial results

Sanofi India Limited's consolidated financial results for the quarter and nine months ended September 30, 2024, show a revenue of ₹5,263 crore, reflecting a growth of 4.9% compared to ₹5,013 crore in the same quarter last year. This growth is driven by improved demand in the pharmaceutical segment and overall market expansion despite operational disruptions from the recent demerger of its Consumer Healthcare business.

The company reported a net profit of ₹822 crore for the quarter, up from ₹806 crore a year ago, translating to an Earnings Per Share (EPS) of ₹35.69, compared to ₹34.99 previously. The financial performance was bolstered by effective cost management, although operational expenses increased slightly, particularly in raw materials and employee benefits.

Operational costs increased by approximately 18% year-over-year, primarily due to heightened purchasing costs and employee benefit expenditures, reflecting strategic investments in workforce retention and material sourcing. This indicates the company's focus on maintaining product availability amid supply chain fluctuations.

While the balance sheet remains robust with total equity of ₹11,540 crore, the company incurred exceptional items related to personnel separation costs amounting to ₹457 crore during the nine-month period.

The strategic outlook appears positive as Sanofi India continues to emphasize innovation and market adaptation post-demerger. Given the stable financial footing and potential for growth in operational efficiency, investors may consider holding their positions as the company navigates its new business landscape and targets expanding its core pharmaceutical operations.